Navigation Links
Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
Date:10/13/2010

Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia... -- SAN FRANCISCO, October 13, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Publishing & Information Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News Click to view news release full screen  

Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco

 

SAN FRANCISCO, October 13, 2010 /PRNewswire-FirstCall/ -- Elsevier Business Intelligence, publisher of PharmAsia News, IN VIVO and "The Pink Sheet," today announced the agenda for Windhover's 2nd PharmAsia Summit (http://www.windhover.com/windhover/content/conferences/pharmasia.aspx) (Oct. 25-26). This year's Summit will bring top biopharma leaders from Asia and the U.S. to San Francisco to share what works and what doesn't in China, India, Japan and the Pacific Rim.

At the PharmAsia Summit, you'll hear Asia strategies and case studies from industry leading experts on dealmaking, commercial strategy, outsourcing, regulatory risks, IP protection, and pricing and reimbursement. Confirmed speakers include:

- Biogen Idec's Gunther Winkler, Senior VP Asia Pacific & Global Government Strategy - Merck's Ramesh Subrahmanian, Senior VP & President of Asia Pacific Human Health - Takeda Research Investment CEO Graeme Martin - Pfizer's Neil Gibson, CSO Oncology Research - Gilead's Clifford Samuel, VP International Access - Advinus Therapeutics CEO Rashmi Barbhaiya - Onyx CEO Anthony Coles - S*Bio CEO Jan-Anders Karlsson - Piramal Life Sciences Managing Director Somesh Sharma - IMS Asia Pacific VP Jan Willem Eleveld - Piper Jaffrey China Healthcare Analyst Hongbo Lu Plus, you'll have a rare opportunity to speak with top Asia regulators, including: - U.S. FDA China Office Director Chris Hickey - U.S. FDA India Office Director Bruce Ross - Shanghai FDA Deputy Director General Yi Chengdong - Korea FDA's Hong Soon-Wook, Director Pharmaceutical Safety Policy

"PharmAsia Summit is a rare opportunity for U.S. biopharma execs to gain an insider's perspective on the most important developments in China, India and Japan without having to cross the Pacific," said Gerry Stoia, president of Elsevier Business Intelligence. "Given the increasing importance of markets like China and India to the biopharma industry, we are honored to host this distinguished group in San Francisco, and hope the Summit will contribute to the dialogue between U.S. and Asia biopharma leaders."

Attendees will in addition learn the latest on China healthcare reform, U.S. FDA actions in China and India, case studies on Japanese dealmaking with U.S. biotechs, novel Asia investment strategies, tips for launching innovative therapies in India and China, opportunities for pre-competitive collaboration that will help de-risk R&D, and finding the right partner in Asia.

Moreover, attendees will catch up on the latest Asian market trends and data from IMS Health, which sees China becoming the third largest pharma market in 2011 and predicts explosive growth in other hot Asia markets like India and Korea.

For further information: http://www.windhover.com/windhover/content/conferences/pharmasia.aspx.

About Windhover Conferences and Elsevier Business Intelligence

Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of "The Pink Sheet," (http://thepinksheet.com) PharmAsia News (http://pharmasianews.com) , "The Tan Sheet" (http://thetansheet), IN VIVO: The Business & Medicine Report ( http://www.windhover.com/windhover/content/publications/index.aspx), Start-Up: Emerging Medical Ventures ( http://www.windhover.com/windhover/content/publications/index.aspx), and The RPM Report: Regulation - Policy - Market Access (http://therpmreport.com/), Elsevier and Windhover also host a variety of industry meetings and webinars in both medical device and pharma/biotech, and produce a wide array of market research reports. For more on the companies' products and services, please visit http://www.ElsevierBI.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com/) and Cell 9http://www.cell.com/), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com/), SciVerse Scopus (http://www.scopus.com/home.url), Reaxys ( http://notice.reaxys.com/maintenance.html), MD Consult ( http://www.mdconsult.com/php/222075573-2/homepage) and Nursing Consult (http://www.nursingconsult.com/php/222075595-2/home.html), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com/) and MEDai's Pinpoint Review (http://www.medai.com/), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com/wps/find/homepage.cws_home) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC ( http://www.reedelsevier.com/Pages/Home.aspx), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact Joshua L. Berlin Elsevier Business Intelligence Mobile: +1-301-538-3527 j.berlin@elsevier.com
'/>"/>

SOURCE Elsevier
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
2. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
3. PDL BioPharma Completes October 1 Special Dividend Payment
4. Genesis Biopharma Announces $700K Private Financing
5. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
6. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
7. Helix BioPharma Approved for NYSE Amex Listing
8. PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
9. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
10. Reportlinker Adds Advances in Biopharmaceutical Technology in China
11. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- UCHealth ( Aurora, Colorado ) becomes ... patient management. In addition to optimizing care coordination for ... lung, UCHealth looks to improve provider workflow by decreasing ... Stephanie Brown, RN , Thoracic Nurse Navigator, says, ... Excel spreadsheet, which was extremely arduous and susceptible to ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... , Feb. 16, 2017 Paradigm Diagnostics ... B financing, adding an additional $3M from New Sciences ... Verde Venture Partners and other strategic partners at the ... further accelerating commercial adoption of their flagship Paradigm Cancer ... expanding the Paradigm cancer registry. Dr. ...
Breaking Biology Technology:
(Date:1/13/2017)... Jan. 13, 2017 Sandata Technologies, LLC, ... the homecare industry, including Electronic Visit Verification™ (EVV™), ... Justin Jugs, as Senior Vice President of Product ... years of homecare experience to Sandata, where he ... plans to align Sandata,s suite of solutions with ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
Breaking Biology News(10 mins):